Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 15 of 15 Matches||Next 20 >>|
1. Neurocognitive differential diagnosis of dementing diseases: Alzheimer's Dementia, Vascular Dementia, Frontotemporal Dementia, and Major Depressive Disorder.
Match Strength: 10.454
Similarities in presentation of Dementia of Alzheimer's Type, Vascular Dementia, Frontotemporal Dementia, and Major Depressive Disorder, pose differential diagnosis challenges. The current study identifies specific neuropsychological patterns of scores for Dementia of Alzheimer's Type, Vascular Dementia, Frontotemporal Dementia, and Major Depressive Disorder. Neuropsychological domains directly assessed in the study included: immediate memory, delayed memory, confrontational naming, verbal fluency, attention, concentration, and executive functioning. The results reveal specific ... Read More »
» Published in Int J Neurosci. 2006 Nov;116(11):1271-93.
2. Long-term lamotrigine plus lithium for bipolar disorder: One year outcome.
Match Strength: 8.389
OBJECTIVE: To obtain pilot data in an observational setting on the use of lamotrigine plus lithium in the long-term treatment of patients with bipolar disorder, 87% of whom had failed to respond to at least one previous mood stabilizer. METHODS: Charts of 21 patients (11 females, 10 males, mean age 43.2 years) treated with the combination of lithium and lamotrigine were reviewed retrospectively for treatment response using the Clinical Global Impression-Bipolar Disorder-Improvement scale, divided into benefit for acute depressive symptoms, acute manic symptoms, and overall illness (including ... Read More »
» Published in J Psychiatr Pract. 2006 Sep;12(5):300-5.
3. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being.
Match Strength: 7.914
OBJECTIVE: We aimed to ascertain the prevalence of obesity in individuals with a mood disorder (MD) (that is, bipolar disorder or major depressive disorder), compared with the general population. We further aimed to examine the likelihood of an association between obesity and MD, while controlling for the influence of sociodemographic variables. METHOD: The analysis was based on data from Statistics Canada's Canadian Community Health Survey: Mental Health and Well-Being (CCHS 1.2), conducted in 2002. The sample (n = 36 984; > or = aged 15 years) was drawn from the Canadian household ... Read More »
» Published in Can J Psychiatry. 2006 Apr;51(5):274-80.
4. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression.
Match Strength: 7.635
OBJECTIVE: To evaluate cognitive-behavioral therapy, antidepressant medication alone, and combined CBT and antidepressant medication in the treatment of depressive disorders in adolescents. METHOD: Seventy-three adolescents (ages 12-18 years) with a primary diagnosis of DSM-IV major depressive disorder, dysthymic disorder, or depressive disorder not otherwise specified were randomly allocated to one of three treatments. Treatment outcome measures were administered before and after acute treatment, and at a 6-month follow-up. Depression diagnosis was the primary outcome measure; secondary ... Read More »
» Published in J Am Acad Child Adolesc Psychiatry. 2006 Oct;45(10):1151-61.
5. Sertraline in children and adolescents with major depressive disorder.
Match Strength: 6.420
OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n = 177) and adolescents (12-17 years old, n = 199) with major depressive disorder. METHOD: A 10-week placebo-controlled treatment was followed by a 24-week open-label sertraline treatment. The double-blind studies were not powered to detect efficacy differences between age groups. A post hoc analysis explored time to first response and first persistent response using the Children's Depression Rating Scale-Revised and ... Read More »
» Published in J Am Acad Child Adolesc Psychiatry. 2006 Oct;45(10):1162-70.
6. Prefrontal hyperactivation during working memory task in untreated individuals with major depressive disorder.
Match Strength: 6.399
The prefrontal cortex, a part of the limbic-thalamic-cortical network, participates in regulation of mood, cognition and behavior and has been implicated in the pathophysiology of major depressive disorder (MDD). Many neuropsychological studies demonstrate impairment of working memory in patients with MDD. However, there are few functional neuroimaging studies of MDD patients during working memory processing, and most of the available ones included medicated patients or patients with both MDD and bipolar disorder. We used functional magnetic resonance imaging (fMRI) to measure prefrontal ... Read More »
» Published in Mol Psychiatry. 2007 Feb;12(2):158-66. Epub 2006 Sep 19.
7. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.
Match Strength: 6.142
The brain-derived neurotrophic factor (BDNF) gene is a candidate gene for influencing the clinical response to treatment with antidepressants. The purpose of this study was to determine the relationship between the Val66Met polymorphism in the BNDF gene and the response to citalopram in a Korean population with major depressive disorder (MDD). Citalopram was administered for 8 weeks to the 83 patients who completed this study. We found that the genotype, allele, and allele-carrier distributions for the Val66Met polymorphism differed significantly between responders (Rp) and nonresponders (Non ... Read More »
» Published in Brain Res. 2006 Nov 6;1118(1):176-82. Epub 2006 Sep 18.
8. Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions.
Match Strength: 5.725
Psychiatric comorbidity is all too common. An important example is the high comorbidity frequency of depressive and anxiety disorders, 25%-50%, much higher than the 5% or less expected by chance. Possible reasons for this comorbidity include definitional, environmental, and biological factors. Few previous studies have assessed, with proper methodology, potential biological changes associated with this co-occurrence. We assessed both hypothalamic-pituitary-adrenocortical axis (HPA) responses to the Trier Social Stress Test and growth hormone (GH) responses to clonidine, a centrally active ... Read More »
» Published in Essent Psychopharmacol. 2006;7(1):24-34.
9. Dimensions underlying outcome criteria in bipolar I disorder.
Match Strength: 5.021
OBJECTIVE: Various subjective and objective criteria are used to assess outcome in bipolar disorder. In this study, we explored to what extent they reflect distinct categories and whether underlying dimensions can be identified. PATIENTS AND METHODS: One-hundred and twenty-one subjects with at least three episodes of bipolar I disorder (DSM-IV) were assessed on average 4.8 years after hospitalization. We assessed 14 variables reflecting different outcome criteria including subjective quality of life (SQOL), self-rated and observer-rated psychopathology, and functioning and disability. A ... Read More »
» Published in J Affect Disord. 2006 Sep 20;
10. Reducing depression stigma using a web-based program.
Match Strength: 5.002
OBJECTIVE: This study was designed to investigate the efficacy and feasibility of a web-based depression stigma education tool for healthcare professionals. METHODS: A web-based depression stigma program utilizing adult learning theories was developed. Forty-two consecutive subjects were enrolled from University of Maryland staff and graduate students. Primary outcomes were Bogardus Social Distance Scale with a vignette on major depression disorder (BSDS-MDD) and the Depression Stigma Scale (DSS) administered before and after the intervention. RESULTS: Internet-based education significantly ... Read More »
» Published in Int J Med Inform. 2006 Sep 19;
11. Emotion recognition patterns in patients with panic disorder.
Match Strength: 4.910
Recognition of facially expressed emotions is essential in social interaction. For patients with social phobia, general anxiety disorders, and comorbid anxiety, deficits in their emotion recognition and specific biases have already been reported. This is the first study to investigate facial emotion recognition patterns in patients with panic disorder [PD]. We assumed a general performance deficit in patients with PD. Exploratory analyses should have revealed recognition patterns and specific types of errors. Additionally, we checked the influence of depression and anxiety symptoms, per se, on ... Read More »
» Published in Depress Anxiety. 2006 Sep 14;
12. Bipolar II and anxious reactive "comorbidity": toward better phenotypic characterization suitable for genotyping.
Match Strength: 4.841
OBJECTIVE: In DSM-IV, bipolar II (BP-II) disorder is defined by depression and hypomania. There is little appreciation of affective instability, often associated with anxiety-particularly panic disorder and agoraphobia (PDA)-comorbidity. This association has genetic-familial implications, which we believe must be incorporated in refining the BP-II phenotype suitable for genotyping purposes. METHOD: We examined in a semi-structured format 107 consecutive patients who met DSM-IV criteria for major depressive episode with atypical features and separated them into two subgroups according to the co ... Read More »
» Published in J Affect Disord. 2006 Dec;96(3):239-47. Epub 2006 Sep 14.
13. Predicting posttraumatic stress symptoms longitudinally in a representative sample of hospitalized injured adolescents.
Match Strength: 4.747
OBJECTIVE: Adolescents constitute a high-risk population for traumatic physical injury, yet few longitudinal investigations have assessed the development of posttraumatic stress disorder (PTSD) symptoms over time in representative samples. METHOD: Between July 2002 and August 2003, 108 randomly selected injured adolescent patients ages 12 to 18 and their parents were interviewed at baseline and again 2, 5, and 12 months postinjury. Initially, participants were screened for PTSD symptoms with the PTSD Reaction Index (PTSD-RI) and depressive symptoms with the Center for Epidemiologic Studies ... Read More »
» Published in J Am Acad Child Adolesc Psychiatry. 2006 Oct;45(10):1188-95.
14. Maintenance treatment of bipolar disorder: Applying research to clinical practice.
Match Strength: 4.318
The authors review available controlled trials of bipolar maintenance treatment and discuss the strengths and weaknesses of various study designs. Bipolar maintenance trials are organized according to the features of their designs, such as use of responder-enriched samples; inclusion following an index manic versus an index depressive episode; outcome defined as relapse into mania, depression, or either; and use of survival analysis. Pivotal studies of lithium, divalproex, lamotrigine, olanzapine, aripiprazole, and other medications are reviewed. The directional efficacy of the different ... Read More »
» Published in J Psychiatr Pract. 2006 Sep;12(5):283-99.
15. Changes in plasma cholesterol in mood disorder patients: Does treatment make a difference?
Match Strength: 3.811
OBJECTIVES: To examine the impact of treatment in patients with acute episodes of major depressive (MD) and manic or hypomanic (M/HM) episodes and co-morbid generalized anxiety symptoms, on the total cholesterol blood levels (TC). METHOD: A consenting series of patients with acute episodes of DSM IV-R confirmed diagnosis of MD or M/H were included. Subjects were treated with antidepressants, mood stabilizers, or both. The Hamilton depression scale (HAM-D21), the modified mania rating scale (MMRS), and the Hamilton anxiety scale (HAM-A) were utilized to evaluate clinical symptoms. Blood samples ... Read More »
» Published in J Affect Disord. 2006 Sep 14;
|<< Prev 20 ||Showing results 1 to 15 of 15||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.